Combination of IDO/Survivin Peptide Vaccine, GM-CSF, Imiquimod and Temozolomide Chemotherapy for Patients With Metastatic Malignant Melanoma
Phase of Trial: Phase II
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Imiquimod (Primary) ; IO 101 (Primary) ; Temozolomide (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 13 Aug 2012 Actual initiation date (May 2012) added as reported by ClinicalTrials.gov.
- 13 Aug 2012 Planned End Date changed from 1 Sep 2013 to 1 Sep 2014 as reported by ClinicalTrials.gov.
- 12 Mar 2012 New trial record